• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to project page

2018 Fiscal Year Final Research Report

Pharmacogenomic study for bleeding risk of direct oral anticoagulants in ischemic cerebral stroke patients

Research Project

  • PDF
Project/Area Number 16K09070
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Research Field Epidemiology and preventive medicine
Research InstitutionKyorin University

Principal Investigator

Ichikawa Yaeko  杏林大学, 医学部, 准教授 (90341081)

Co-Investigator(Kenkyū-buntansha) 平野 照之  杏林大学, 医学部, 教授 (50346996)
Project Period (FY) 2016-04-01 – 2019-03-31
Keywords直接阻害型経口抗凝固薬 / 脳梗塞 / 脳塞栓症 / ファーマコゲノミクス / 一塩基多型 / CES1 / ABCB1
Outline of Final Research Achievements

This prospective study was aimed to identify biomarkers for bleeding risk of direct oral anticoagulants (DOAC) in cerebral stroke patients. We investigated the allele frequencies and the genotypes of CES1: rs2244613 and ABCB1: rs4148738 polymorphisms in 22 Japanese patients with cerebral stroke. These polymorphisms were reported to be associated with the dabigatran concentrations and the risk of bleeding in dabigatran-treated Caucasian patients. The minor allele (C allele) of CES1: rs2244613 polymorphism was associated with lower trough concentrations and a lower risk of bleeding (Circulation, 2013). In our Japanese patients, the C allele frequency of CES1: rs2244613 polymorphism was 52%, which was higher than in the Caucasian participants of RE-LY Trial (18%). Bleeding events have not occurred in our patients during this study. Further studies are needed to clarify the association between the polymorphisms and the bleeding risk of DOAC in Japanese patients with cerebral stroke.

Free Research Field

神経内科学

Academic Significance and Societal Importance of the Research Achievements

脳塞栓症の二次予防を目的とした抗凝固療法において、ワルファリンに代わり、DOACが使われるようになった。DOACは血液凝固機能のモニタリングは不要とされるが、適切な薬物療法を行うために、出血性副作用を回避する指標が求められている。本研究は、欧米の先行研究でDOACとの関連が明らかとなった遺伝子多型について、日本人で検証した。年齢と腎機能の観点からDOACを選択したところ、現時点までに脳梗塞再発および出血性副作用はみられていない。今後も経過を追って、出血性副作用と遺伝子型との関連を検討していく。出血性副作用を予測するバイオマーカーの同定は、個人の薬物代謝能力に応じた個別化治療への礎となる。

URL: 

Published: 2020-03-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi